Intrasense Launches Myrian® XP-FemalePelvis for the Diagnosis and Follow-up of Ovarian and Cervical Cancers

Regulatory News:

INTRASENSE (Paris:ALINS), a leader in multimodal medical imaging software, announces the launch of its new module Myrian® XP-FemalePelvis for the visualization and the multiparametric analysis of female pelvis MR exams.

Every year, 240,000 ovarian cancers and 530,000 cervical cancers are diagnosed worldwide (World Cancer Research Fund International, 2012).

Magnetic Resonance Imaging (MRI) is the modality recommended by the European Society of Urogenital Radiology (ESUR) for the diagnosis and follow-up of these two cancers. This modality provides a large amount of functional and morphological data that require specific reading and interpretation tools and workflows.

Based on the recommendations from ESUR, Myrian® XP-FemalePelvis implements the concept of Structured Reading™ developed by Intrasense. The user is thus guided through the analysis of female pelvis MRI exams according to the guidelines provided by the scientific society. In addition to optimizing reading workflows and generating considerable timesaving, this increases the consistency of data analysis, facilitates comparison with prior exams or exams from other modalities and enhances diagnosis quality.

Moreover, Myrian® XP-FemalePelvis automates the creation of powerful and comprehensive reports including key images and data for an optimized communication between healthcare professionals and with the patient herself.

Patrick Mayette, Intrasense CEO, comments: « This new module further enhances our oncology offer. Intrasense, the specialist of solutions for the diagnosis and analysis of images in oncology and chronic diseases, is leading the way in the advanced reading and analysis of MRI exams. We provide tangible answers to the challenges and expectations of radiologists, oncologists and specialists. This is absolutely key as this approach enables to focus on what matters most: patients’ safety.”

About Intrasense:
Created in 2004 with an innovative technology of tissues detection in CT scan, Intrasense designs, develops and markets Myrian®, a unique, vendor-neutral software suite for the visualization and advanced processing of multimodal medical images such as MRI, CT scans, PET, X-rays, and more. Developed with leading academic and scientific partners, Myrian® combines and uses all of the various medical images to extract information vital to the patient's care, to evaluate treatment efficiency and to assess drug candidates in oncology and other pathologies. With more than 700 client sites around the world, Myrian® has been certified as a "medical device" in over 40 countries including the United States (FDA), Europe (CE) and Asia. Intrasense SA is listed on the Alternext (FR0011179886 - ALINS). The company employs 70 people, including 25 dedicated in R&D. Labelled "innovative company” by Oseo, Intrasense has invested over 9 M€ in R&D since its creation.
For more about Intrasense, please visit www.intrasense.fr and follow us on LinkedIn.